Clinicopathologic features and management of blastoid variant of mantle cell lymphoma

Rajesh Shrestha, Vijaya R Bhatt, Guru Subramanian Guru Murthy, James Olen Armitage

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The blastoid variant of mantle cell lymphoma (MCL), which accounts for less than one-third of MCL, may arise de novo or as a transformation from the classical form of MCL. Blastoid variant, which predominantly involves men in their sixth decade, has frequent extranodal involvement (40-60%), stage IV disease (up to 85%) and central nervous system (CNS) involvement. Diagnosis relies on morphological features and is challenging. Immunophenotyping may display CD23 and CD10 positivity and CD5 negativity in a subset. Genetic analysis demonstrates an increased number of complex genetic alterations. Blastoid variant responds poorly to conventional chemotherapy and has a short duration of response. Although the optimal therapy remains to be established, CNS prophylaxis and the use of aggressive immunochemotherapy followed by autologous stem cell transplant may prolong the remission rate and survival. Further studies are crucial to expand our understanding of this disease entity and improve the clinical outcome.

Original languageEnglish (US)
Pages (from-to)2759-2767
Number of pages9
JournalLeukemia and Lymphoma
Volume56
Issue number10
DOIs
StatePublished - Oct 3 2015

Fingerprint

Mantle-Cell Lymphoma
Central Nervous System
Immunophenotyping
Stem Cells
Survival Rate
Transplants
Drug Therapy
Therapeutics

Keywords

  • Mantle cell lymphoma
  • autologous stem cell transplant
  • blastoid variant
  • central nervous system involvement
  • genetic alteration
  • high dose chemotherapy
  • intensified chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. / Shrestha, Rajesh; Bhatt, Vijaya R; Guru Murthy, Guru Subramanian; Armitage, James Olen.

In: Leukemia and Lymphoma, Vol. 56, No. 10, 03.10.2015, p. 2759-2767.

Research output: Contribution to journalReview article

Shrestha, Rajesh ; Bhatt, Vijaya R ; Guru Murthy, Guru Subramanian ; Armitage, James Olen. / Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 10. pp. 2759-2767.
@article{d7c0893357b34ccca0b6f1474b5a0d2c,
title = "Clinicopathologic features and management of blastoid variant of mantle cell lymphoma",
abstract = "The blastoid variant of mantle cell lymphoma (MCL), which accounts for less than one-third of MCL, may arise de novo or as a transformation from the classical form of MCL. Blastoid variant, which predominantly involves men in their sixth decade, has frequent extranodal involvement (40-60{\%}), stage IV disease (up to 85{\%}) and central nervous system (CNS) involvement. Diagnosis relies on morphological features and is challenging. Immunophenotyping may display CD23 and CD10 positivity and CD5 negativity in a subset. Genetic analysis demonstrates an increased number of complex genetic alterations. Blastoid variant responds poorly to conventional chemotherapy and has a short duration of response. Although the optimal therapy remains to be established, CNS prophylaxis and the use of aggressive immunochemotherapy followed by autologous stem cell transplant may prolong the remission rate and survival. Further studies are crucial to expand our understanding of this disease entity and improve the clinical outcome.",
keywords = "Mantle cell lymphoma, autologous stem cell transplant, blastoid variant, central nervous system involvement, genetic alteration, high dose chemotherapy, intensified chemotherapy",
author = "Rajesh Shrestha and Bhatt, {Vijaya R} and {Guru Murthy}, {Guru Subramanian} and Armitage, {James Olen}",
year = "2015",
month = "10",
day = "3",
doi = "10.3109/10428194.2015.1026902",
language = "English (US)",
volume = "56",
pages = "2759--2767",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Clinicopathologic features and management of blastoid variant of mantle cell lymphoma

AU - Shrestha, Rajesh

AU - Bhatt, Vijaya R

AU - Guru Murthy, Guru Subramanian

AU - Armitage, James Olen

PY - 2015/10/3

Y1 - 2015/10/3

N2 - The blastoid variant of mantle cell lymphoma (MCL), which accounts for less than one-third of MCL, may arise de novo or as a transformation from the classical form of MCL. Blastoid variant, which predominantly involves men in their sixth decade, has frequent extranodal involvement (40-60%), stage IV disease (up to 85%) and central nervous system (CNS) involvement. Diagnosis relies on morphological features and is challenging. Immunophenotyping may display CD23 and CD10 positivity and CD5 negativity in a subset. Genetic analysis demonstrates an increased number of complex genetic alterations. Blastoid variant responds poorly to conventional chemotherapy and has a short duration of response. Although the optimal therapy remains to be established, CNS prophylaxis and the use of aggressive immunochemotherapy followed by autologous stem cell transplant may prolong the remission rate and survival. Further studies are crucial to expand our understanding of this disease entity and improve the clinical outcome.

AB - The blastoid variant of mantle cell lymphoma (MCL), which accounts for less than one-third of MCL, may arise de novo or as a transformation from the classical form of MCL. Blastoid variant, which predominantly involves men in their sixth decade, has frequent extranodal involvement (40-60%), stage IV disease (up to 85%) and central nervous system (CNS) involvement. Diagnosis relies on morphological features and is challenging. Immunophenotyping may display CD23 and CD10 positivity and CD5 negativity in a subset. Genetic analysis demonstrates an increased number of complex genetic alterations. Blastoid variant responds poorly to conventional chemotherapy and has a short duration of response. Although the optimal therapy remains to be established, CNS prophylaxis and the use of aggressive immunochemotherapy followed by autologous stem cell transplant may prolong the remission rate and survival. Further studies are crucial to expand our understanding of this disease entity and improve the clinical outcome.

KW - Mantle cell lymphoma

KW - autologous stem cell transplant

KW - blastoid variant

KW - central nervous system involvement

KW - genetic alteration

KW - high dose chemotherapy

KW - intensified chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84947545571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947545571&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1026902

DO - 10.3109/10428194.2015.1026902

M3 - Review article

C2 - 25747972

AN - SCOPUS:84947545571

VL - 56

SP - 2759

EP - 2767

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -